Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. 

Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes

A recent study published in Diabetes Care investigates the accuracy of continuous glucose monitoring (CGM) compared to traditional blood glucose measurements for hemodialysis patients with diabetes. The study, conducted on 31 patients using the Dexcom G6 CGM, found a moderate correlation between CGM and blood glucose readings, with a mean difference of around +15 mg/dL. Although accuracy was lower during hemodialysis, error grids indicated that nearly all CGM readings were within clinically acceptable ranges. The findings highlight the potential for CGM use in this patient group, though further research is needed to confirm its benefits.

Terumo Blood and Cell Technologies kicks off U.S. launch of Reveos Automated Blood Processing System with Blood Centers of America Used globally for over a decade in 50+ countries, Reveos targe...

Terumo Blood and Cell Technologies launched the Reveos™ Automated Blood Processing System in the U.S., designed to streamline whole blood processing into components like platelets, plasma, and red blood cells. This new system improves efficiency, reduces labor, and addresses platelet shortages by automating the process, which traditionally required over 20 manual steps. Carter BloodCare in Texas and Blood Centers of America are among the first to implement the system, highlighting its role in optimizing blood centers’ operations and managing staffing challenges.

German Health Award for Beurer

Beurer GmbH has been named a winner of the 2024 German Health Award, securing recognition in two categories: "Digital Heart Centers & Mobile ECG" and "Meters for Blood Pressure and Pulse – Brand Apps." The award, organized by news channel ntv and the German Institute for Service Quality (DISQ), evaluates customer satisfaction and highlights leading healthcare providers. Out of 553 companies assessed, over 45,000 respondents participated in the survey, which covered factors such as value for money, offerings, customer service, and willingness to recommend.

Type 1 Diabetes Market Size to Reach USD 63.5 Billion by 2032, With 7.82% CAGR

The Type 1 Diabetes Market, valued at USD 32.3 billion in 2023, is projected to reach USD 63.5 billion by 2032, growing at a CAGR of 7.82%. The market is driven by rising incidence among children and adolescents and advancements in diabetes management technologies, such as insulin pumps and pens, which provide better glycemic control. Key players, including Eli Lilly, Medtronic, and Novo Nordisk, are leading innovations in insulin delivery systems. North America dominates the market, while the Asia Pacific region is the fastest-growing, fueled by cost-effective treatments and increased healthcare spending.

The $2.62bn Diabetes Devices Industry Landscape in Germany, 2024-2032 - Personalized Medicine and AI Drive Growth in the Advanced Diabetes Devices Market

The Germany Diabetes Device market is projected to grow from US$ 1.39 billion in 2023 to US$ 2.62 billion by 2032, with a CAGR of 7.3%. Key players like Abbott, Roche, and Medtronic are leading innovation in insulin pumps, continuous glucose monitors (CGMs), and blood glucose meters. The market's rapid growth is driven by rising diabetes prevalence, technological advancements, and the German government's focus on preventative care and chronic disease management. Digital health solutions, such as telemedicine and AI-driven devices, are playing an increasingly significant role in improving patient engagement and outcomes.

Eyenuk Teams with the American Academy of Ophthalmology to Provide AI-Driven Eye Disease Screening for Delaware’s Underserved Populations

Eyenuk, a leader in AI-powered digital health solutions, has partnered with the American Academy of Ophthalmology’s EyeCare America program to offer diabetic retinopathy screenings to underserved communities in Delaware. Using Eyenuk’s FDA-cleared EyeArt® AI Eye Screening system, Federally Qualified Health Centers (FQHCs) can now provide autonomous diabetic retinopathy detection during routine primary care visits. This program aims to reduce preventable blindness among low-income populations by offering early screening and referrals for treatment. Early results show that 26% of patients screened had vision-threatening conditions, highlighting the importance of accessible eye care.

Dario Expands GLP-1 Solution Client Base with New Employer Contract

DarioHealth Corp. has secured a new contract with a national employer in the environmental services sector to provide its cardiometabolic solution, which includes integrated support for employees using GLP-1 medications. The program will address conditions like diabetes, pre-diabetes, hypertension, and weight management, helping employees sustain positive health outcomes. Dario's data-driven approach and personalized engagement, strengthened by its acquisition of Twill, aim to keep users engaged long-term, addressing the challenge that 68% of people stop GLP-1 medications within a year, risking weight regain.

China Diabetes Device Market Forecast Report 2024-2032 - China's Population with Type 1 Diabetes Is Growing, China's Diabetes Device Market is Set to Reach US$ 12.74 Billion by 2032

China's diabetes device market is expected to grow significantly, from USD 6.22 billion in 2023 to USD 12.74 billion by 2032, driven by the increasing prevalence of diabetes and rising demand for advanced management solutions like glucose meters, insulin pumps, and continuous glucose monitoring (CGM) systems. Government initiatives, such as reducing medical costs and promoting National Metabolic Management Centers, play a key role in improving diabetes care. International and domestic companies are actively expanding in the market, with recent collaborations aiming to provide cutting-edge diabetes technologies to address the growing public health challenge.

Glooko scores $100M and appoints new CEO

Glooko, the maker of a digital platform for managing diabetes and other chronic diseases, has secured $100 million in Series F funding and announced Mike Alvarez as the company's newly appointed CEO.  Georgian led the round with participation from Canaan, Health Catalyst Capital, and other investors and business partners. The California-based company will use the funds to scale its product expansion globally. 

Alvarez formerly held the CEO role at Qardio, a remote patient monitoring and healthcare technology company for chronic disease management. Before that, he held leadership positions at medical device maker Medtronic, pharma company Sanofi and St. Jude Medical, which was acquired by Abbott.